دورية أكاديمية
أعرض في EDS

Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.

التفاصيل البيبلوغرافية
العنوان: Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.
المؤلفون: Kemp DE; Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA. kemp.david@gmail.com, Karayal ON, Calabrese JR, Sachs GS, Pappadopulos E, Ice KS, Siu CO, Vieta E
المصدر: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [Eur Neuropsychopharmacol] 2012 Feb; Vol. 22 (2), pp. 123-31. Date of Electronic Publication: 2011 Jul 28.
نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9111390 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7862 (Electronic) Linking ISSN: 0924977X NLM ISO Abbreviation: Eur Neuropsychopharmacol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier, c1990-
مواضيع طبية MeSH: Adjuvants, Immunologic/*therapeutic use , Antipsychotic Agents/*therapeutic use , Bipolar Disorder/*drug therapy , Body Weight/*drug effects , Metabolic Diseases/*drug therapy , Piperazines/*therapeutic use , Thiazoles/*therapeutic use, Bipolar Disorder/complications ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Lithium Chloride/therapeutic use ; Longitudinal Studies ; Male ; Metabolic Diseases/etiology ; Metabolome/drug effects ; Psychiatric Status Rating Scales ; Valproic Acid/therapeutic use
مستخلص: This analysis was conducted to compare the effects of adjunctive ziprasidone or placebo on metabolic parameters among patients receiving maintenance treatment with lithium or valproate. We also tested whether metabolic syndrome (MetS) and other risk factors were associated with baseline characteristics and treatment response. In the stabilization phase (Phase 1), 584 bipolar I disorder (DSM-IV) patients received 2.5-4 months of open label ziprasidone (80-160 mg/d) plus lithium or valproic acid (ZIP+MS). Patients who achieved at least 8 weeks of clinical stability were subsequently randomized into Phase 2 to 6-months of double-blind treatment with ZIP+MS (n=127) vs. placebo+MS (n=113). At baseline of Phase 1, MetS was found in 111 participants (23%). Participants with MetS (vs. non-MetS participants) were more likely to be aged 40 years or older, had significantly more severe manic symptoms, higher abdominal obesity, and higher BMI. Increase in abdominal obesity was associated with lower manic symptom improvement (p<0.05, as assessed by MRS change score) during Phase 1, while symptom improvement differed across racial groups. In the Phase 2 double-blind phase, the ZIP+MS group had similar weight and metabolic profiles compared to the placebo+MS group across visits. These results corroborate existing findings on ziprasidone which exhibits a neutral weight and metabolic profile in the treatment of schizophrenia and bipolar patients. Our findings suggest that MetS is highly prevalent in patients with bipolar disorder, may be associated with greater manic symptom severity, and may predict treatment outcomes.
(Copyright © 2011 Elsevier B.V. All rights reserved.)
References: J Clin Psychiatry. 2006 Apr;67(4):575-83. (PMID: 16669722)
J Affect Disord. 2010 Nov;126(3):366-87. (PMID: 20541810)
Arch Gen Psychiatry. 2001 Sep;58(9):844-50. (PMID: 11545667)
Diabetes Care. 2005 Nov;28(11):2745-9. (PMID: 16249550)
J Clin Psychiatry. 2010 Apr;71(4):391-9. (PMID: 20021992)
J Clin Psychiatry. 2006 May;67(5):783-8. (PMID: 16841628)
Neuropsychobiology. 2006;53(2):108-12. (PMID: 16557041)
J Clin Psychiatry. 2006 Jul;67(7):1055-61. (PMID: 16889448)
Neuropsychobiology. 2003;47(3):146-51. (PMID: 12759558)
Am J Psychiatry. 2003 Jan;160(1):112-7. (PMID: 12505809)
Am J Psychiatry. 2006 Feb;163(2):247-56. (PMID: 16449478)
Neuropsychopharmacology. 2008 Apr;33(5):985-94. (PMID: 17637612)
Bipolar Disord. 2007 Jun;9(4):394-412. (PMID: 17547586)
Lancet. 2004 Jan 10;363(9403):157-63. (PMID: 14726171)
J Psychiatr Pract. 2011 Mar;17(2):100-9. (PMID: 21430488)
N Engl J Med. 2005 Sep 22;353(12):1209-23. (PMID: 16172203)
Trends Endocrinol Metab. 2010 Jun;21(6):345-52. (PMID: 20223680)
J Clin Psychiatry. 2001 Apr;62(4):273-81. (PMID: 11379842)
J Affect Disord. 2008 Jan;105(1-3):45-52. (PMID: 17498812)
Bipolar Disord. 2009 May;11(3):225-55. (PMID: 19419382)
Schizophr Res. 2008 Feb;99(1-3):13-22. (PMID: 18053689)
Acta Psychiatr Scand. 2008 Jul;118(1):4-18. (PMID: 18498432)
Am J Psychiatry. 2009 Apr;166(4):476-88. (PMID: 19289454)
Psychiatry Res. 2003 May 30;118(2):137-45. (PMID: 12798978)
Neurosci Biobehav Rev. 2008;32(4):675-92. (PMID: 18199480)
Pharmacol Ther. 2010 Jan;125(1):169-79. (PMID: 19931306)
Arch Gen Psychiatry. 2005 Oct;62(10):1089-96. (PMID: 16203954)
Psychiatry Res. 2009 Dec 30;170(2-3):172-6. (PMID: 19897253)
J Affect Disord. 2005 May;86(1):1-10. (PMID: 15820265)
J Clin Psychiatry. 2010 Feb;71(2):130-7. (PMID: 20122373)
Natl Health Stat Report. 2009 May 5;(13):1-7. (PMID: 19634296)
Diabetes Care. 2009 Jun;32(6):1037-42. (PMID: 19244091)
Obes Rev. 2001 May;2(2):73-86. (PMID: 12119665)
CNS Drugs. 2005;19 Suppl 1:1-93. (PMID: 15998156)
J Clin Psychopharmacol. 2007 Aug;27(4):365-8. (PMID: 17632220)
Lancet. 2004 Mar 13;363(9412):902. (PMID: 15031055)
Schizophr Res. 2009 May;110(1-3):103-10. (PMID: 19321312)
J Clin Psychiatry. 2006 Apr;67(4):626-37. (PMID: 16669728)
Endocrinology. 1990 Oct;127(4):1689-96. (PMID: 2401232)
Bipolar Disord. 2010 Jun;12(4):404-13. (PMID: 20636638)
J Clin Psychiatry. 2010 Sep;71(9):1138-44. (PMID: 20492838)
J Clin Endocrinol Metab. 1998 Mar;83(3):847-50. (PMID: 9506738)
Schizophr Res. 2005 Dec 1;80(1):19-32. (PMID: 16137860)
J Affect Disord. 2008 Aug;109(3):251-63. (PMID: 18579216)
Int Clin Psychopharmacol. 2008 Jul;23(4):216-22. (PMID: 18545060)
J Affect Disord. 2008 Feb;106(1-2):197-201. (PMID: 17631970)
Pharmacoepidemiol Drug Saf. 2009 Sep;18(9):791-9. (PMID: 19526626)
Bipolar Disord. 2005 Oct;7(5):424-30. (PMID: 16176435)
J Affect Disord. 2002 Apr;68(2-3):167-81. (PMID: 12063145)
Circulation. 2005 Oct 25;112(17):2735-52. (PMID: 16157765)
J Clin Psychiatry. 2004 Dec;65(12):1679-87. (PMID: 15641874)
معلومات مُعتمدة: KL2 RR024990 United States RR NCRR NIH HHS; KL2 RR024990-02 United States RR NCRR NIH HHS
المشرفين على المادة: 0 (Adjuvants, Immunologic)
0 (Antipsychotic Agents)
0 (Piperazines)
0 (Thiazoles)
614OI1Z5WI (Valproic Acid)
6UKA5VEJ6X (ziprasidone)
G4962QA067 (Lithium Chloride)
تواريخ الأحداث: Date Created: 20110730 Date Completed: 20120423 Latest Revision: 20240604
رمز التحديث: 20240604
مُعرف محوري في PubMed: PMC3225596
DOI: 10.1016/j.euroneuro.2011.06.005
PMID: 21798721
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-7862
DOI:10.1016/j.euroneuro.2011.06.005